Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor Academic Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Enzyme Inhibitors
  • Protein-Tyrosine Kinases
  • Quinazolines
  • Receptor, Epidermal Growth Factor

abstract

  • Erlotinib has inhibitory biologic effects on normal surrogate tissues and on an EGFR-positive tumor. The lack of reduced tumor proliferation may be attributed to the heterogeneous expression of receptor in the EGFR-positive patient and absence of target in this cohort of heavily pretreated patients.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.08.189

PubMed ID

  • 15284258

Additional Document Info

start page

  • 3080

end page

  • 90

volume

  • 22

number

  • 15